Cell programmed necrosis inhibitors, methods for producing the same, and uses

A structurally novel RIPK1 inhibitor, represented by formula I, addresses the limitations of existing inhibitors by effectively inhibiting RIPK1 in both inactive and activated states, providing rapid treatment for programmed necrosis-related diseases with enhanced safety and brain penetration.

JP2026523173APending Publication Date: 2026-07-13SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025574245
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-05
Filing Date
2024-07-04
Publication Date
2026-07-13

AI Technical Summary

Technical Problem

Existing RIPK1 inhibitors face challenges such as safety issues in chronic diseases affecting the central nervous system, limited brain penetration, and structural limitations that hinder optimization and validation in preclinical disease models, necessitating novel compounds with high activity, specificity, and blood-brain barrier permeability.

Method used

Development of a structurally novel compound represented by formula I, which includes specific aromatic rings, substituents, and functional groups, designed to inhibit RIPK1 kinase activity and programmed necrosis pathways.

Benefits of technology

The compound effectively inhibits both inactive and activated RIPK1, offering rapid symptom relief and treatment for diseases related to programmed necrosis and inflammation, with improved safety and brain penetration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026523173000001_ABST
    Figure 2026523173000001_ABST
Patent Text Reader

Abstract

The present invention provides a cell-programmed necrosis inhibitor, a method for producing the same, and its use. Specifically, the present invention provides a compound represented by formula I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. The present invention also provides a method for producing the compound, a pharmaceutical composition containing the same, or its use in the treatment or prevention of diseases or conditions related to cell-programmed necrosis and / or human receptor-interacting protein kinase 1 (RIPK1). JPEG2026523173000068.jpg42170
Need to check novelty before this filing date? Find Prior Art